KR20020092886A - 재조합 아데노바이러스 - Google Patents

재조합 아데노바이러스 Download PDF

Info

Publication number: KR20020092886A
Authority: KR; South Korea
Prior art keywords: adenovirus; fiber; seq; fragment; recombinant
Prior art date: 1999-07-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

KR1020027000132A

Other languages

English (en)

Korean (ko)

Inventor

레이프 린돌름

Original Assignee

고트-아-겐 에이비

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-06

Filing date

2000-06-30

Publication date

2002-12-12

1999-07-06 Priority claimed from SE9902601A external-priority patent/SE9902601D0/xx

2000-06-30 Application filed by 고트-아-겐 에이비 filed Critical 고트-아-겐 에이비

2002-12-12 Publication of KR20020092886A publication Critical patent/KR20020092886A/ko

Status Withdrawn legal-status Critical Current

Links

241000701161 unidentified adenovirus Species 0.000 title claims abstract description 52
239000000835 fiber Substances 0.000 claims abstract description 122
239000003446 ligand Substances 0.000 claims abstract description 32
238000005829 trimerization reaction Methods 0.000 claims abstract description 31
238000000034 method Methods 0.000 claims abstract description 18
230000003612 virological effect Effects 0.000 claims abstract description 9
201000010099 disease Diseases 0.000 claims abstract description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
238000001727 in vivo Methods 0.000 claims abstract description 3
210000004027 cell Anatomy 0.000 claims description 70
239000012634 fragment Substances 0.000 claims description 31
108090000623 proteins and genes Proteins 0.000 claims description 24
108090000765 processed proteins & peptides Proteins 0.000 claims description 16
108010077850 Nuclear Localization Signals Proteins 0.000 claims description 15
241000700605 Viruses Species 0.000 claims description 15
229940024606 amino acid Drugs 0.000 claims description 13
108700026758 Adenovirus hexon capsid Proteins 0.000 claims description 8
101150008132 NDE1 gene Proteins 0.000 claims description 8
108091008874 T cell receptors Proteins 0.000 claims description 7
102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 7
238000011144 upstream manufacturing Methods 0.000 claims description 6
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 6
101800003838 Epidermal growth factor Proteins 0.000 claims description 5
101150052859 Slc9a1 gene Proteins 0.000 claims description 5
229940116977 epidermal growth factor Drugs 0.000 claims description 5
241000588724 Escherichia coli Species 0.000 claims description 4
108060003951 Immunoglobulin Proteins 0.000 claims description 4
101100442582 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) spe-1 gene Proteins 0.000 claims description 4
150000001413 amino acids Chemical class 0.000 claims description 4
238000010367 cloning Methods 0.000 claims description 4
210000000805 cytoplasm Anatomy 0.000 claims description 4
230000006801 homologous recombination Effects 0.000 claims description 4
238000002744 homologous recombination Methods 0.000 claims description 4
102000018358 immunoglobulin Human genes 0.000 claims description 4
238000012986 modification Methods 0.000 claims description 4
230000004048 modification Effects 0.000 claims description 4
102100024025 Heparanase Human genes 0.000 claims description 3
101001047819 Homo sapiens Heparanase Proteins 0.000 claims description 3
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 3
239000003205 fragrance Substances 0.000 claims description 3
230000001965 increasing effect Effects 0.000 claims description 3
102000004169 proteins and genes Human genes 0.000 claims description 3
101150116497 sacm1l gene Proteins 0.000 claims description 3
210000001519 tissue Anatomy 0.000 claims description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
101710128836 Large T antigen Proteins 0.000 claims description 2
101001038021 Lonomia obliqua Lopap Proteins 0.000 claims description 2
101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 claims description 2
241000191940 Staphylococcus Species 0.000 claims description 2
238000005516 engineering process Methods 0.000 claims description 2
230000002068 genetic effect Effects 0.000 claims description 2
239000003102 growth factor Substances 0.000 claims description 2
230000001900 immune effect Effects 0.000 claims description 2
102000006495 integrins Human genes 0.000 claims description 2
108010044426 integrins Proteins 0.000 claims description 2
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims description 2
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
230000001172 regenerating effect Effects 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
230000004083 survival effect Effects 0.000 claims description 2
FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims 1
102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
101710188053 Protein D Proteins 0.000 claims 1
101710132893 Resolvase Proteins 0.000 claims 1
210000004072 lung Anatomy 0.000 claims 1
238000000338 in vitro Methods 0.000 abstract description 4
239000000796 flavoring agent Substances 0.000 abstract description 2
235000019634 flavors Nutrition 0.000 abstract description 2
238000001415 gene therapy Methods 0.000 description 14
239000013598 vector Substances 0.000 description 14
206010028980 Neoplasm Diseases 0.000 description 13
230000030648 nucleus localization Effects 0.000 description 9
210000002845 virion Anatomy 0.000 description 8
125000003275 alpha amino acid group Chemical group 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
241001135569 Human adenovirus 5 Species 0.000 description 6
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 5
238000012744 immunostaining Methods 0.000 description 5
102400001368 Epidermal growth factor Human genes 0.000 description 4
101710145505 Fiber protein Proteins 0.000 description 4
230000006870 function Effects 0.000 description 4
YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 3
101100462537 Caenorhabditis elegans pac-1 gene Proteins 0.000 description 3
101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 3
101001057131 Homo sapiens Melanoma-associated antigen D4 Proteins 0.000 description 3
102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 3
101100117764 Mus musculus Dusp2 gene Proteins 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
239000013638 trimer Substances 0.000 description 3
241000701447 unidentified baculovirus Species 0.000 description 3
241000238631 Hexapoda Species 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
208000006265 Renal cell carcinoma Diseases 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000008859 change Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000025308 nuclear transport Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
238000002823 phage display Methods 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
230000008685 targeting Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
210000004128 D cell Anatomy 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
108010020195 FLAG peptide Proteins 0.000 description 1
108010035452 HLA-A1 Antigen Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
102000048850 Neoplasm Genes Human genes 0.000 description 1
108700019961 Neoplasm Genes Proteins 0.000 description 1
208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
206010039509 Scab Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
108700025771 adenovirus penton Proteins 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
230000003302 anti-idiotype Effects 0.000 description 1
230000007416 antiviral immune response Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
210000004671 cell-free system Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000012636 effector Substances 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000012215 gene cloning Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000010189 intracellular transport Effects 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000006911 nucleation Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
108091008819 oncoproteins Proteins 0.000 description 1
102000027450 oncoproteins Human genes 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
230000009385 viral infection Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- C12N2810/405—Vectors comprising RGD peptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/854—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from hormones
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Virology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Plant Pathology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

KR1020027000132A 1999-07-06 2000-06-30 재조합 아데노바이러스 Withdrawn KR20020092886A (ko)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
SE9902601A SE9902601D0 (sv)	1999-07-06	1999-07-06	Recombinant adenovirus
SE9902601-5		1999-07-06
US14363299P	1999-07-14	1999-07-14
US60/143,632		1999-07-14
PCT/SE2000/001390 WO2001002431A1 (fr)	1999-07-06	2000-06-30	Adenovirus recombinant

Publications (1)

Publication Number	Publication Date
KR20020092886A true KR20020092886A (ko)	2002-12-12

Family

ID=26663617

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020027000132A Withdrawn KR20020092886A (ko)	1999-07-06	2000-06-30	재조합 아데노바이러스

Country Status (7)

Country	Link
EP (1)	EP1196435A1 (fr)
JP (1)	JP2003531568A (fr)
KR (1)	KR20020092886A (fr)
CN (1)	CN1359391A (fr)
AU (1)	AU763733B2 (fr)
CA (1)	CA2378324A1 (fr)
WO (1)	WO2001002431A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2407518A1 (fr) *	2000-04-26	2001-11-01	Crucell Holland B.V.	Vecteurs d'adenovirus a fibres sans spicule, et leurs utilisations
AU6368901A (en)	2000-05-31	2001-12-11	Univ Saskatchewan	Modified bovine adenovirus having altered tropism
GB0017720D0 (en) *	2000-07-19	2000-09-06	Got A Gene Ab	Modified virus
DK1733736T3 (en) *	2001-02-07	2015-06-01	Wilex Ag	A process for the production of recombinant antibodies to tumors
US20040077081A1 (en)	2001-02-07	2004-04-22	Egbert Oosterwijk	Hybridoma cell line g250 and its use for producing monoclonal antibodies
US7632496B2 (en)	2002-07-01	2009-12-15	Wilex Ag	Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
AU2005310604A1 (en) *	2004-11-30	2006-06-08	Kiim Pharm Lab. Inc.	Anti-HIV drug, polypeptide constituting the same, gene encoding the polypeptide and method of producing the anti-HIV drug
WO2007094653A1 (fr) *	2006-02-13	2007-08-23	Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg	Particules adénovirales ayant une protéine s adénovirale chimérique, et utilisation et procédés de production de ces particules
EP2248903A1 (fr)	2009-04-29	2010-11-10	Universitat Autònoma De Barcelona	Procédés et réactifs pour le transfert génétique efficace et ciblé vers des monocytes et macrophages
CN102775500A (zh) *	2012-08-03	2012-11-14	郑骏年	嵌合抗原受体iRGD-scFv(G250)-CD8-CD28-CD137-CD3ζ及其用途
SG11201507393TA (en)	2013-03-14	2015-10-29	Salk Inst For Biological Studi	Oncolytic adenovirus compositions
CN104634978A (zh) *	2013-11-13	2015-05-20	长春百克生物科技股份公司	一种分型检测腺病毒中和抗体的方法以及用于分型检测腺病毒中和抗体的试剂盒
KR102608590B1 (ko)	2014-09-24	2023-12-01	솔크 인스티튜트 포 바이올로지칼 스터디즈	종양 살상 바이러스 및 이의 사용방법
CN107683289B (zh) *	2015-01-26	2021-08-06	芝加哥大学	IL13Rα2结合剂和其在癌症治疗中的用途
WO2017147265A1 (fr)	2016-02-23	2017-08-31	Salk Institute For Biological Studies	Dosage à haut débit pour mesurer la cinétique de réplication d'un adénovirus
WO2017147269A1 (fr)	2016-02-23	2017-08-31	Salk Institute For Biological Studies	Expression de gènes exogènes dans un adénovirus thérapeutique pour un effet minimal sur la cinétique virale
EP3532082A4 (fr)	2016-12-12	2020-08-26	Salk Institute for Biological Studies	Adénovirus synthétiques ciblant une tumeur et leurs utilisations
CN107602672B (zh) *	2017-08-30	2021-06-18	广州医科大学附属第一医院	重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法
CN107365365B (zh) *	2017-08-30	2021-01-01	广州医科大学附属第一医院	重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法
CN112292449A (zh)	2018-04-09	2021-01-29	萨克生物研究学院	具有增强的复制特性的溶瘤腺病毒组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5770442A (en) *	1995-02-21	1998-06-23	Cornell Research Foundation, Inc.	Chimeric adenoviral fiber protein and methods of using same
EE9800160A (et) *	1995-11-28	1998-12-15	Genvec, Inc.	Vektorid ja meetodid geenide ülekandmiseks rakkudesse
JP2001520511A (ja) *	1995-12-08	2001-10-30	ザユーナヴァーサティオブアラバマアトバーミングハムリサーチファンデーション	向標的性アデノウイルス・ベクター
AU751542B2 (en) *	1998-02-17	2002-08-22	Uab Research Foundation, The	Modified adenovirus containing a fiber replacement protein

2000
- 2000-06-30 WO PCT/SE2000/001390 patent/WO2001002431A1/fr not_active Ceased
- 2000-06-30 CN CN00809885A patent/CN1359391A/zh active Pending
- 2000-06-30 KR KR1020027000132A patent/KR20020092886A/ko not_active Withdrawn
- 2000-06-30 AU AU60401/00A patent/AU763733B2/en not_active Ceased
- 2000-06-30 JP JP2001508218A patent/JP2003531568A/ja active Pending
- 2000-06-30 CA CA002378324A patent/CA2378324A1/fr not_active Abandoned
- 2000-06-30 EP EP00946680A patent/EP1196435A1/fr not_active Withdrawn

Also Published As

Publication number	Publication date
CA2378324A1 (fr)	2001-01-11
WO2001002431A1 (fr)	2001-01-11
AU763733B2 (en)	2003-07-31
AU6040100A (en)	2001-01-22
JP2003531568A (ja)	2003-10-28
CN1359391A (zh)	2002-07-17
EP1196435A1 (fr)	2002-04-17

Legal Events

Date	Code	Title	Description
2002-01-05	PA0105	International application	Patent event date: 20020105 Patent event code: PA01051R01D Comment text: International Patent Application
2002-12-12	PG1501	Laying open of application
2005-07-01	PC1203	Withdrawal of no request for examination
2005-07-01	WITN	Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid

Publication	Publication Date	Title
KR20020092886A (ko)	2002-12-12	재조합 아데노바이러스
Krasnykh et al.	2000	Genetic targeting of adenoviral vectors
CA2213343C (fr)	2009-09-01	Proteine fibreuse chimere d'adenovirus et ses procedes d'utilisation
US6455314B1 (en)	2002-09-24	Alternatively targeted adenovirus
ES2246533T3 (es)	2006-02-16	Fibra adenovirica modificada y adenovirus dianas.
US5712136A (en)	1998-01-27	Adenoviral-mediated cell targeting commanded by the adenovirus penton base protein
AU734515B2 (en)	2001-06-14	A short-shafted adenoviral fiber and its use
JP2001503250A (ja)	2001-03-13	束縛ペプチドモチーフを用いたターゲッティングアデノウイルス
Medina-Kauwe et al.	2001	3PO, a novel nonviral gene delivery system using engineered Ad5 penton proteins
AU2002344190B8 (en)	2002-12-09	Adenovirus protein IX, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
AU2002344190A1 (en)	2003-05-08	Adenovirus protein IX, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
JP2003508057A (ja)	2003-03-04	改変アデノウイルスファイバーおよび用途
JP4683682B2 (ja)	2011-05-18	平滑筋細胞および／または内皮細胞への組織向性を与えられた遺伝子送達ベクター
AU2004238979B2 (en)	2008-12-18	Broadening adenovirus tropism
US20030149235A1 (en)	2003-08-07	Targeting peptides
US6815200B1 (en)	2004-11-09	Modified adenovirus containing a fiber replacement protein
CA2256696C (fr)	2007-03-20	Petits virus a arn modifies
Medina-Kauwe	2002	A Novel Gene Delivery System Targeted to fireast Cancer Cells
Mikheeva et al.	0	Genetic Targeting of an Adenovirus Vector
Miller	1999	Modification of the viral and cellular requirements for adenovirus entry into cells
Curiel	2001	Conditionally Replicative Adenovirus for Prostate Cancer Therapy